Dear colleagues,
The WHO just released the report of the 20th Expert Committee on the Selection and Use of Essential Medicines, and the application for the inclusion of misoprostol on the Model List of Essential Medicines (EML) for the additional indication of treating postpartum hemorrhage when oxytocin is not available or cannot be used safely, was accepted!
You can access the report and the 2015 EML through the links here: Report of the 20th WHO Expert Committee >> on the Selection and Use of Essential Medicines; 2015 WHO Model list of Essential Medicines >>
Thanks to all of you who sent in your own letters of support or signed the FIGO letter of support which included the signatures of over 150 organizations and individuals from across the globe. This is really great news as the EML provides an internationally recognizable set of selected medicines which helps countries choose how to treat their priority health needs. Inclusion on this list enables many countries to develop their own national EML, assists national decision-makers in reducing costs by identifying priority medicines, and plays an important advocacy role for non-governmental organizations to try to make these priority medicines available and accessible. This ultimately helps to expand the range of available options to treat postpartum hemorrhage.
With thanks to you all for your continued dedication to maternal health.
Kind regards,
Jessica Morris
FIGO Project Manager
International Federation of Gynecology and Obstetrics
FIGO House, Suite 3, Waterloo Court, 10 Theed Street,
London SE1 8ST, United Kingdom
Tel: +44 (0)20 7928 1166
Skype: jessica.l.morris
Web: http://www.figo.org
|
